ProPhase Labs, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
ProPhase Labs, Inc. (PRPH) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $5.38 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2025-04-01
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-12-31 was $0.00.
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-09-30 was $0.00.
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-06-30 was $0.00.
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-03-31 was $5.38M.
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $5.38M, a 28.03% decline from fiscal 2022.
- ProPhase Labs, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $7.47M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $0.00 derived: sum of 3 quarters · filed 2025-04-01 | $5.38M 10-K · filed 2025-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $5.38M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.38M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $5.38M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $7.47M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |